Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

METEOR study

Financiado

MicrobiomE-associaTEd boosters Of immune Responses (METEOR study): experimental...

MicrobiomE-associaTEd boosters Of immune Responses (METEOR study): experimental charac-terization and clinical exploitation. I became fascinated by pathogen-host interactions at the end of my PhD, working with Hepatitis C virus, and later in my first postdoctoral phase working with Influenza A and SARS-2 viruses, when I learned the OMIC technologies pow... ver más

31/12/2025

FUNDACION PARA LA...

193K€

Presupuesto del proyecto: 193K€

Líder del proyecto

FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL... Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 130K€

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-22

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100% 100%

4 Participantes

FUNDACION PARA LA INVESTIGAC...

192.87K€ | Lider

MIKROBIOMIK HEALTHCARE COMPA...

N.D. | Participante

University of Colorado Denve...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

OPATHY From Omics to Patient Improving Diagnostics of Pathogenic Y... 3M€ Cerrado

RYC2021-033955-I Development of personalized ecosystem models for host-microb... 236K€ Cerrado

BiomeDxRx Microbiome-based diagnostics and therapeutics 150K€ Cerrado

SAF2009-13032-C02-01 METAGENOMICA POBLACIONAL DE COMUNIDADES MICROBIANAS HUMANAS 392K€ Cerrado

MetaboGutModel Resolving metabolic interactions between the gut microbiota... 1M€ Cerrado

VESICULOME Origin, evolution and function of bacterial extracellular ve... 2M€ Cerrado

Duración del proyecto: 42 meses Fecha Inicio: 2022-06-22
Fecha Fin: 2025-12-31

Líder del proyecto

FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL... Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 130K€

Presupuesto del proyecto 193K€

Descripción del proyecto I became fascinated by pathogen-host interactions at the end of my PhD, working with Hepatitis C virus, and later in my first postdoctoral phase working with Influenza A and SARS-2 viruses, when I learned the OMIC technologies power. Finally, I found out about the world of microbiota-associated interactions and how Dr. Serrano’s studies unveiled these complex networks with a clinical perspective. Most microbiota studies are based on the description of the different bacterial species profiles. How-ever, the interactions between the byproducts derived from cells and bacteria can affect reciprocally to host and microbial metabolism, modifying the outcome of the disease. With my expertise on experi-mental settings, Dr Serrano’s clinical-research view, and the strong collaborations with expert partners in bioinformatics and multi-omics, for my next career step I aim to develop experimental strategies to better identify new potential therapeutic agents. Specifically, to clinically exploit MIcrobiome-associated BOosters of Immune responses to infectious Diseases (MIBOIDs) that define the nature of the host-microbiota interaction I will implement a protocol based on directed culturomics, immune stimulations assays, bacterial species description and multi-omic toolbox to characterize the functional immune profiles associated with highly protective immune responses, and data mining through a mul-tiparametric bioinformatic integration approach. We aim to test several conditions such as describing gut microbiota from different compartments, microbial communities from localized disease-related tissues, and to describe the most functionally relevant. Finally, after the production and validation of the specific candidates in vitro, this project will lead to future validation in preclinical and clinical studies to get specific MIBOIDs to be exploited as therapeutic agents aimed at improving disease-specific immune responses, prevention and cure for several diseases.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores